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Highlights 
 Current parenteral nutrition treatment is understudied 
 Health-related quality of life and physical function may be improved by current parenteral 
nutrition treatment during anti-neoplastic treatment in malnourished patients unable to feed 
enterally, but not necessarily in patients with functional gastrointestinal tract 
 Nutritional status may be improved by current PN treatment, regardless of anti-neoplastic 
treatment and gastrointestinal function 
 Current parenteral nutrition treatment is not superior to dietary counselling in patients with 
functional gastrointestinal tract nor to fluid treatment in terminal patients in relation to survival  














Background: The aim was to evaluate the effects of current parenteral nutrition (PN) treatment on 
clinical outcomes in patients with advanced cancer. 
Methods: This review was conducted according to the PRISMA guidelines (PROSPERO ID: 
4201707915). 
Results: Two underpowered randomized controlled trials and six observational studies were 
retrieved (n=894 patients). Health-related quality of life and physical function may improve during 
anti-neoplastic treatment in who PN treatment is the only feeding opportunity, but not necessarily in 
patients able to feed enterally. Nutritional status may improve in patients regardless of anti-
neoplastic treatment and gastrointestinal function. PN treatment was neither superior to fluid in 
terminal patients nor to dietary counselling in patients able to feed enterally in regards to survival. 
The total incidence of adverse events was low. 
Conclusion: Current PN treatment in patients with advanced cancer is understudied and the level of 
evidence is weak.   
Keywords: Palliative care; Intravenous nutrition; performance status; weight loss; cachexia; 




Patients with advanced cancer frequently experience weight loss. High symptom burden in 
combination with side effects from anti-neoplastic treatments and metabolic derangement syndromes, 
such as cachexia, lead to inadequate food intake, inactivity and/or functional decline, which promotes 
anorexia, fatigue and catabolism [1, 2]. Moreover, patients in a palliative care setting may have a life 
expectancy of several months to years, and some still receive anti-neoplastic treatment, making them 













Nutritional guidelines for patients with advanced cancer recommend nutritional interventions only 
after carefully considering the prognosis and expected benefit on health-related quality of life 
(HRQoL) and potential survival [2]. The treatment goals of parenteral nutrition (PN) administration 
should be to maintain HRQoL and performance status [2]. The guidelines recommend PN in patients 
with chronic insufficient dietary intake if enteral nutrition is not sufficient or feasible and/or if patients 
have uncontrollable malabsorption. However, the level of evidence supporting the beneficial effects 
of PN is weak [2]. Health care professionals are often challenged when selecting which patients with 
advanced cancer should receive PN and deciding when to terminate PN due to the uncertainties of 
expected individual benefits. 
 
A meta-analysis from 1990 demonstrated a net harm of PN administration with trends in reduced 
survival and tumour response and an increased incidence of infectious complications in patients 
receiving PN during chemotherapy [3]. The authors concluded that routine use of PN should be 
strongly discouraged and that trials involving specific groups of patients should be undertaken with 
caution [3]. As a consequence of this conclusion, no randomized controlled trials (RCTs) involving 
patients with advanced cancer were conducted during the next several decades. Administration 
techniques have improved, and considerable changes have been made to the dosage, composition and 
distribution of PN macronutrients. Thus, there is a need for an updated systematic review 
investigating the effect of current PN administration in patients with advanced cancer. The primary 
aims of this systematic review are to evaluate the effect of PN administration on HRQoL and physical 
function (self-reported, performance status or physical performance testing). The secondary outcomes 
evaluated were nutritional status, survival, tolerance and dose-limiting toxicity to anti-neoplastic 













This systematic review was conducted according to the Preferred Reporting for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [4]. A Cochrane technology platform was used to manage 
the review process [5]. The review protocol was registered at the International Prospective Register 
of Systematic Reviews (PROSPERO) (ID: CRD4201707915). 
 
2.1 Search strategy and selection criteria 
A systematic literature search was conducted by a research librarian using the Ovid MEDLINE, 
EMBASE, CINAHL EBSCOhost and The Cochrane Library databases on the 13th of September 2017 
(Appendix 1). An updated search was conducted the 18th of May 2018. A hand search for additional 
relevant articles from references of key articles was also performed. Screening and eligibility 
assessments were conducted by two independent reviewers (RT and TRB) using the following 
criteria: prospective clinical trials or retrospective studies involving adults (≥ 16 years) diagnosed 
with any incurable/advanced cancers (defined as not curable but might respond to cancer treatment 
or disease-directed therapy to prolong life and reduce symptoms) who received any type or regimen 
of PN treatment compatible with current practices (at home or in a hospital/institution) that reported 
HRQoL outcomes, physical function (self-reported, performance status or physical performance 
testing), nutritional status (nutritional assessments, body weight or fat free mass), survival, tolerance 
or dose-limiting toxicity to anti-neoplastic treatment and adverse events associated with PN 
administration. PN treatment compatible with current practise is defined in this review as 
normocaloric infusion (not hypercaloric) and PN solution containing fatty acids, amino acids and 
glucose, preferably in all-in-one bags. Any uncertainties in assessing the eligibility of the studies were 
discussed among the authors until a consensus was reached. Studies were excluded if patients 












post-operatively to assess complications related to surgery, patients were <16 years old, patients had 
mixed malignant and benign diseases or the evaluated populations of cancer patients had different 
stages of disease (in which no subgroup analysis of an advanced cancer population was possible to 
retrieve), populations of less than 10 patients or less than 20 patients with more than three different 
cancer diagnoses, the intervention consisted of dietary counselling, enteral feeding, intravenous 
hydration, or the initiation of PN was not defined in studies using combined treatment with enteral 
nutrition strategies. Non-English articles were excluded. 
 
2.2 Data collection process and data items 
A data extraction table was developed, pilot tested and refined within the review group. Data were 
extracted by two review authors (RT and TRB) and evaluated independently by a third author (LT). 
Overall survival was assumed to be calculated from the time of initiation of PN administration, unless 
otherwise stated in the article. 
 
2.3 Assessment of risk of bias 
The content of each of the included RCTs was analysed using methodological risk of bias domains 
from the Cochrane Handbook for Systematic Reviews of Interventions at the study level [6]. All 
reviewers assessed the risk of bias (RoB), and any discrepancies were resolved through discussion. 
There is no single recommended instrument for assessing the RoB when the systematic review also 
includes non-randomized trials [6]. Therefore, the Institute of Health Economics (IHE) Quality 
Appraisal Checklist for Case Series Studies was opted for the observational studies [7]. The quality 
appraisal checklist consists of 20 criteria, of which 16 criteria were considered important. Pre-defined 
aspects considered important were determined for the study population (age, sex, cancer diagnosis, 












description of the intervention (composition of the PN solution, administration, rate, dosage, duration 
and indications). When assessing the overall quality of the observational studies, the studies were 
categorized as good or poor quality based on pre-defined cut-off scores. A total score was calculated 
by summarizing scores from each of the 16 predefined criteria (3 points for yes, 2 points for partially 
and 1 point for no/unclear reporting) and categorized as good (score of 40-48) or poor quality (score 
of 16-39). A study was classified as good quality if at least 4 out of 6 reviewers scored the study at 
40-48 points. RoB and confounders were assessed. 
3. Results 
 3.1 Search results and selection of studies 
The literature review retrieved 1039 papers (Figure 1). Three additional studies were identified by 
hand searching. After excluding duplicates and studies that did not meet the inclusion criteria based 
on title and abstract screening, 85 papers were selected for full-text examination. Full-text screening 
resulted in the exclusion of 64 papers (for reasons, see Figure 1). Additionally, 13 studies were 
excluded based on critically high RoB [8-20] (Appendices 2 and 3). The present review is based on 
the results from eight articles: two RCTs [21, 22], five prospective observational studies [23-27] and 
one retrospective study [28]. 
 
3.2 Risk of bias 
A summary of the qualitative RoB assessment for the included studies can be seen in Tables 1 and 2. 
Both RCTs were underpowered, as only 47 of the planned 100 patients [22] and 31 of the planned 
116 patients were enrolled [21]. Most of the observational studies had a high risk of attrition bias as 
well as performance bias due to poor reporting of PN administration and lack of systematic reporting 













 3.3 Study and patient characteristics 
Detailed study characteristics of the included trials can be seen in Table 3 and some major study 
characteristics are listed in Table 4. Two RCTs (n=78), five prospective studies (n=664) and one 
retrospective study (n=152) yielded a total of 894 patients, of who 857 received PN. The population 
size in the individual studies ranged from 31 to 414 and included 435 females (46%), 414 males 
(49%) and 45 patients (5%) whose sex was not reported. The patients’ mean age was 60.8 years 
(range, 16 – 90 years). Six of eight studies included different cancer diagnoses [21, 23-25, 27, 28]. A 
total of 28 cancer diagnoses were counted, of which gastric, colorectal, pancreatic and gynaecological 
cancers were the most common. In total, 223 patients (25%) received concurrent anti-neoplastic 
treatment [22, 24, 25, 27], and 639 patients (71%) did not [21, 23-25, 28] (Table 4). One study (n=32, 
4%) did not report the use of concurrent anti-neoplastic treatment [26]. 
 
A wide range of methods were used to assess nutritional status at baseline. Four studies used validated 
screening or assessment tools for (risk of) undernutrition (Malnutrition Universal Screening Tool 
(MUST) [25], Nutritional Risk Screening 2002 (NRS2002) [22], Subjective Global Assessment 
(SGA) [27] or Patient-Generated Subjective Global Assessment (PG-SGA) [24]). Body mass index 
(BMI) was reported by two RCTs [21, 22] and by five observational studies [23, 24, 26-28]. Weight 
loss was reported in various ways: weight loss over the last three months [24], weight loss over the 
last six months [27, 28], percent weight loss of usual weight (usual not specified) [23] and weight 
loss without a specified time frame [22]. Oral food intake was reported by one RCT [22] and one 













All patients were either considered at risk of undernutrition or malnourished at inclusion. Two studies 
used patients’ (risk of) undernutrition specifically as an inclusion criterion, of which one RCT used 
the score of ≥2 on the NRS2002 [22] and one observational study used a weight loss of ≥5% over the 
previous four weeks or a BMI (kg/m2) < 19 [26]. Additionally, three studies used nil/negligible intake 
per os or enteral feeding as inclusion criteria [21, 23, 24].  
 
Baseline performance status was reported in seven of eight studies using either the Karnofsky 
Performance Score (KPS) [23, 24, 27, 28] or Eastern Cooperative Oncology Group (ECOG) 
performance status [21, 22, 25] (Table 3 and 4). The two RCTs had performance status as an inclusion 
criterion: ECOG performance status of 0-2 [22] or ECOG performance status of 3 or 4 [21]. The mean 
performance status at baseline reported in the observational studies was a KPS of 60 (range, 20-100) 
[23, 24, 27, 28] and ECOG performance status of 1.5 (standard deviation (SD), 0.5) [25]. 
 
All studies reported the indications for initiating PN (Table 3). In 79 % of the patients, the primary 
PN indication was compromised gastrointestinal function (obstruction, short bowel syndrome or 
fistula formation) [21, 23-28] (Table 4). No or negligible food intake/enteral nutrition was the primary 
PN indication in 16% of the patients [21, 23, 24, 26]. Lastly, in the remaining 5 % of the patients, PN 
was provided to patients in an attempt to prevent functional decline in malnourished patients not 
otherwise indicated for PN (functional gastrointestinal tract and food intake above 75 % of the energy 
and protein requirement in most of the patients) [22]. 
 
 3.4 Intervention 
The composition of PN solutions was reported in most studies, albeit the degree of reported details 












reported the composition of PN macronutrient solution [21, 25, 26], while one study failed to describe 
the composition of PN [23]. The method of PN administration was reported by four studies and 
included via a central venous catheter (CVC) [22, 23, 25, 28], transthoracic venous port [22] or 
peripherally inserted central catheter (PICC) line [22]. The administration rate was described by five 
studies [22, 24-27]; in four studies PN was preferably delivered during the night [22, 24-26], and one 
study reported using daily cyclic infusions [27]. None of the studies reported the infusion rate (e.g., 
continuous infusion or ml/min). The planned energy dose ranged between 20-35 kcal/kg/day [23-25, 
27, 28] and 25 kcal/kg/day in five out of seven days [26]. The planned protein dose ranged between 
1.0 and 2.5 g/kg/d [23-28]. In one RCT, PN contributed 25-35% of the planned intake (30 kcal/kg/day 
and 1.5 g protein/kg/day), as the patients had a substantial oral intake [22]. One study did not report 
a planned dose of either calories or protein and reported only the amount of calories administered 
(average 1286 kcal/day) [21]. Additionally, three studies reported the calories administered but did 
not confirm whether patients reached target goals [22, 24, 27]. The duration of PN administration 
varied among the studies, ranging from a median of 9 days [21] to 6 months [22]. Two studies reported 
administering PN until death or close to death in all patients [21, 28] and until death in approximately 
66% of the patients in one study [23]. The median duration of PN administration was < 1 month in 
one study [21], 1-3 months in three studies [23, 25, 28] and > 3 months in four studies [22, 24, 26, 
27]. 
 
 3.5 Effects of PN on HRQoL 
Three studies provided data on HRQoL (n=210) (Table 5). HRQoL was assessed by different methods 
(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 
(EORTC QLQ-C30) [24, 27] and EORTC QLQ-C15-PAL [22]) and measured at different time points 












months [24] or 24 weeks [22]). In one RCT, a significantly higher mean (95% confidence interval 
(CI)) score of +16 (0.6, 31) points in HRQoL at 12 weeks was reported in favour of PN compared to 
control treatment (p<0.05), but not at week 6, 18 or 24 [22]. In one observational study, HRQoL was 
unchanged after one month but significantly improved after two (+12 points, p=0.02) and three 
months (+24 points, p=0.02) [27]. Another observational study reported significant improvement over 
time during four months using analysis of repeated measures (p<0.001), with +6 points at one month, 
+14 points at two months, +19 points at three months and +14 points at four months [24]. In summary, 
the effect of current PN treatment on HRQoL in patients with advanced cancer is poorly investigated. 
PN was superior in a transient manner to dietetic counselling in patients with functional 
gastrointestinal tract while undergoing anti-neoplastic treatment. In patients where PN is the only 
viable feeding option, HRQoL may improve after a minimum of two months on PN in malnourished 
patients while undergoing anti-neoplastic treatment. Although statistical significance was reached, 
the reported effect sizes does not necessarily reach clinical relevant improvements in HRQoL (< 20 
%).   
 
 3.6 Effects of PN on physical function 
Three studies provided data on self-reported physical function from subscales of HRQoL 
questionnaires (n=210) [22, 24, 27] (Table 5). An RCT found no difference between patients 
receiving PN and control subjects at any time during the 24 weeks of intervention [22]. The two 
observational studies reported improved self-reported physical function over time ((+4 points at one 
month, +8 points at two months, +17 points at three months and +14 points at four months; p<0.001 
for repeated measures) [24] and after two (+14 points, p=0.02) and three months (+16 points, 













One RCT [22], one prospective study [27] and one retrospective study [28] reported a change in 
performance status as assessed by health providers’ perception of patients’ function (KPS) or physical 
performance tests (strength or endurance) (n=251) (Table 3). Patients randomized to receive PN or 
control treatment both improved on the 6-minute walk test and in terms of hand grip strength from 
baseline to week 24 in the RCT, although no significant difference between the two arms was found 
[22]. In the prospective study, there was a significant increase in KPS after one (+6 points, p=0.01), 
two (+10 points, p=0.01) and three months (+15 points, p=0.002) [27]. In the retrospective study, 
there was no change in KPS after one month in subgroups of survivors after >60 and >90 days [28], 
but no data from patients who survived less than 60 or 30 days were reported. 
 
In summary, the effect of current PN treatment on physical function in patients with advanced cancer 
is poorly investigated. PN was not superior to dietetic counselling in malnourished patients with 
functional gastrointestinal tract undergoing active anti-neoplastic treatment. However, PN may be 
beneficial in malnourished patients when PN is the only feeding opportunity and who still receive 
anti-neoplastic treatment, but not in patients not undergoing anti-neoplastic treatment.  
 
 3.7 Effects of PN on nutritional status 
Nutritional status was reported in 4 of 8 studies (n=283) [22, 26-28] (Table 5). In one RCT, the mean 
(95% CI) BMI and fat free mass was significantly increased at week 12 in favour of the supplementary 
PN arm compared to the control arm (mean (95% CI): +1.65 (0.4, 2.9) BMI (kg/h2), p<0.05; +6.44 
kg (2.9, 10.0) FFM (kg), p<0.01) [22]. No differences between the two arms on any nutritional status 
outcomes were observed at the other time points (week 6, 18 or 24) [22]. Two observational studies 
(n=251) reported an increase in mean body weight (kg) by 1.5 kg in subgroups of survivors after >60 












months [27] (p<0.05). One observational study reported a mean increase in BMI of 0.5 kg/m2 at one 
month in subgroups of survivors after >60 and >90 days (p=0.0001) [28]. No data were presented for 
survivors after <60 days [28]. Another observational study reported a median increase in BMI of 0.7 
kg/m2 (no effect per time unit or p value reported) [26]. One observational study reported nutritional 
status using the SGA global rating, and the of patients in category SGA-A (well nourished) changed 
from zero patients at baseline, to two patients at 1 month and three patients at 2 months, SGA-B 
(moderately malnourished) changed from 19 patients at baseline to 20 patients at 1 month, 13 patients 
at 2 months, and 12 patients at 3 months, while the number of patients in category SGA-C (severely 
malnourished) decreased from 33 patients at baseline to 17 patients at 1 month, 6 patients at 2 months 
and one patient at 3 months [27]. 
 
In summary, current PN treatment seems to be superior to dietetic counselling in a transient manner 
in regards to BMI and fat free mass in malnourished patients with functional gastrointestinal tract, 
while undergoing anti-neoplastic treatment. When PN is the only feeding opportunity, PN may 
improve nutritional status in malnourished patients regardless of anti-neoplastic treatment after 2-3 
months of PN treatment.  
 
 3.8 Effects of PN on survival 
Data on survival were available from seven studies (n=862) [21-25, 27, 28] (Table 5). In the RCT 
involving terminal patients, the median overall survival (mOS) was 8 days (95% CI: 5.7-10.3) in the 
control group compared to 13 days (95% CI: 3.1-22.9) in the PN group [21]. In the other RCT, the 
mOS was 169 (95% CI: 88-295) days in the control group versus 168 (95% CI: 88-268) days in the 
supplemental PN group [22]. The difference in mOS between patients receiving PN compared to 












the observational studies, the mOS in months was 3 (95% CI: 2.7-3.3) [23], 5.1 (95% CI: 2.8-7.3) 
[27] and 4.7 (range, 1-42) months [24]. In the two observational studies reporting survival in days, 
the mOS (range) was 40 (2-702) [25] and 45 (6-1269) days [28]. In summary, survival between 
patients receiving and not receiving current PN treatment is poorly investigated and both RCTs were 
underpowered. PN is neither superior to dietetic counselling in patients with functional 
gastrointestinal tract undergoing anti-neoplastic treatment, nor superior to fluid administration in 
terminal patients.  
 
3.9 Effects of PN on tolerance and dose-limiting toxicity of anti-neoplastic treatment 
No studies reported outcomes on tolerance or dose-limiting toxicity of anti-neoplastic treatment. 
 
3.10 Effects of PN on adverse events 
Adverse events were systematically reported in four of eight studies (n=245) [22, 24-26] (Table 5). 
One observational study reported no adverse events [26]. One RCT reported catheter-related 
infections in two patients but no episodes of severe catheter-related blood stream infection [22]. One 
observational study reported catheter-related infections in 3.6% of the patients [25], while another 
observational study reported an incidence of catheter-related bloodstream infection of 0.33 per 1000 
catheter-days [24]. Two additional studies reported discontinuation of PN due to PN-related 
complications (n=466) [23, 27]: catheter-related complications in nine of 414 patients (incidence: 
2.2%) [23], sepsis in two of 52 patients [27] and elevated liver function tests in two of 52 patients 
[27]. Death due to PN/CVC complications was reported in five of 414 patients (incidence: 1.2%) [23] 
and liver dysfunction in one patient after nine months on PN [27]. In summary, the incidence of 














3.11 Losses to follow-up 
Losses to follow-up were reported in or could be retrieved from all studies. Three studies assessed 
survival as the only outcome, and all patients were included in the survival analysis [21, 23, 25]. One 
study performed an analysis in survivors over the previous 60 and 90 days; however, they presented 
conflicting numbers of losses to follow-up between the text and tables [28]. No patients were lost to 
follow-up in one study [26], while the remaining three studies reported losses to follow-up by stating 
the number of patients included at each time point of assessment [22, 24, 27]. The cumulative losses 
to follow-up were 27 of 163 patients at one month (17%) [24, 27], 11 of 47 patients at six weeks 
(23%) [22], 65 of 163 patients at two months (40%) [24, 27], 116 of 210 patients at three months 
(55%) [22, 24, 27], 57 of 111 patients at four months (51%) [24], 25 of 47 at 18 weeks (53%) [22] 
and 30 of 47 patients at six months (64%) [22]. The main reason for loss to follow-up was death or 
worsening of the clinical state (98 of 210 patients (47%) [22, 24, 27]). Other reasons included weaning 
from PN to oral feeding or enteral nutrition, change in home care company, refusal to continue PN or 
adverse events [23, 24, 27]. 
4. Discussion 
This systematic review selectively assessed the effect of current PN treatment exclusively in patients 
with advanced cancer. Since the launch of PN treatment, the most important advancement in this 
therapy is the reduction of the glucose load by implementing fatty acids in the PN solution and 
reducing the caloric load to match the caloric demand, as well as improving the hygiene protocols. 
Trials using outdated PN strategies (hypercaloric, glucose rich PN therapies) were thus excluded in 
order to assess the effects of PN treatment more compatible with today’s practice. The evidence level 
of all outcomes is weak, due to the few high quality trials. Effects on HRQoL and physical function 












malnourished patients with functional gastrointestinal tract during anti-neoplastic treatment. Two of 
the observational studies were conducted in malnourished patients in who PN was the only viable 
feeding option and received concurrent anti-neoplastic treatment. One retrospective study that 
assessed physical function was conducted in malnourished patients in who PN was the only viable 
feeding option without concurrent anti-neoplastic treatment. In malnourished patients receiving anti-
neoplastic treatment and in who PN was the only available feeding route, PN may improve HRQoL, 
physical function and nutritional status after two months of PN treatment. On the contrary, 
malnourished patients receiving anti-neoplastic treatment, with a moderate spontaneous food intake 
and who could be fed via enteral route, PN was not superior to dietary counselling in regards to 
HRQoL, physical function, nutritional status or survival during a six month intervention, apart from 
a transient effect on HRQoL and nutritional status at three months. In malnourished patients, no 
longer candidates to receive anti-neoplastic treatment, current PN treatment can improve nutritional 
status, but not physical function.      
 
Unlike simple undernutrition (non-disease-related malnutrition [1]), a negative energy balance and 
muscle loss in patients with cancer cachexia is characterized by a combination of reduced food intake 
and catabolism driven by systemic inflammation [29]. Earlier practices of hypercaloric PN aimed to 
reverse catabolism, particularly by use of high doses of glucose [3]. High energy-dense lipid 
emulsions have later been integrated into PN solutions, thus reducing the glucose load and high 
volume infusion. Furthermore, the use of soybean oil rich in pro-inflammatory n-6 polyunsaturated 
fatty acids (PUFAs) has been replaced with olive oil and fish oil, which are rich in anti-inflammatory 
n-3 PUFAs [30, 31]. Cachexia cannot be reversed by nutritional support alone [29]; thus, hypercaloric 
PN is no longer the standard of care. Nevertheless, the optimal PN treatment for these patients is still 












response to energy balance is uncertain [29, 32]. Following the meta-analysis on survival and adverse 
events from 1990 evaluating RCTs using hypercaloric and glucose-rich PN solutions [3], two 
previous systematic reviews have assessed the clinical effects of PN in patients with inoperable 
malignant bowel obstruction [33, 34]. Both reviews failed to provide a conclusion on HRQoL due to 
the use of non-validated QoL tools used by the majority of the individual studies [33, 34]. 
Furthermore, these reviews included studies using outdated PN treatment, such as hypercaloric PN, 
and consequently cannot be used to evaluate the efficacy of current PN treatment. 
 
The studies conducted in recent years have predominantly been observational, and these studies can 
provide important information about prevalence and adverse events. Nevertheless, observational 
studies cannot provide reliant effect sizes for key questions regarding the effects of PN on clinically 
relevant outcomes due to bias and confounding factors. The observed effects could, for instance, be 
a response to anti-neoplastic treatment, symptom alleviation and loss of patients with initially poor 
nutritional/clinical status (“survivalism”) and underpin the importance of a control group when the 
effects of an intervention are evaluated. The importance of an actual control group is exemplified by 
one RCT in which both arms showed increased physical performance and a transient increase in 
muscle mass in 40% of the patients in the control arm [22]. 
 
The major limitations of this review were the lack of well-designed RCTs. Both RCTs were 
underpowered and did not comply with indications for PN treatment according to guidelines [2]. 
Patients in one study were terminally ill with days or a few weeks of expected survival [21], while 
the majority of patients in the other RCT had a nutritional intake above 75% of the estimated 
requirement and a functional gastrointestinal (GI) tract [22]. PN administration is neither indicated in 












recommended nutritional intake and a functional GI tract [2]. A multicentre phase III RCT involving 
patients with advanced cancer aimed at study the effect of PN on HRQoL was recently completed 
[35]. The inclusion criteria comply with indications for PN administration according to guidelines 
and will, if positive, identify causal effects of PN on HRQoL and other important outcomes in patients 
with advanced cancer. Future studies must provide detailed descriptions regarding PN administration, 
including planned and administered dosages, sufficiency of caloric intake compared to nutritional 
requirements, composition, infusion rate, and duration, to gather information on the optimal PN 
treatment. For better reporting of nutritional interventions, investigators can find guidance using a 
checklist [36]. 
4. Conclusion 
This systematic review is the first to evaluate the effects of current PN treatment exclusively in 
patients with advanced cancer. The evidence is weak for all outcomes and is predominantly based on 
observational studies. During anti-neoplastic treatment, PN seems to improve HRQoL and physical 
function in patients who PN is the only viable feeding option, but not necessarily in patients able to 
be fed enterally. Regardless of anti-neoplastic treatment and GI function, nutritional status seems to 
be improved by current PN treatment in malnourished patients. No benefit on survival of PN in 
terminal patients or patients able to feed enterally were reported. The frequency of adverse effects 
was low; however, a lack of systematic reporting was observed. Further RCTs with sufficient number 
of patients of clinically homogenous subgroups are urgently needed.  
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Figure 1. Flow chart for the study selection process. 
The figure provides details of reasons for exclusion of full text articles 
 
aStudies excluded based on poor quality appraisal, as assessed by a total score < 40 on the IHE 
Quality Appraisal Checklist for case series studies. 
 
Records excluded due to poor quality 
appraisala  
(n = 13) 
Study quality assessment  
(n = 21) 
Records identified through 
database searching  































Additional records identified 
through other sources  
(n = 3) 
Records after duplicates removed  
(n = 573) 
Titles and abstracts screened  
(n = 573) 
Records excluded  
(n = 488) 
Full-text articles assessed 
for eligibility  
(n = 85) 
Full-text articles excluded, with reasons  
(n = 64) 
 
Non-English articles (n=21) 
n < 10 OR n<20 if > 3 cancer types (n= 7) 
Mixed cancer stage OR mixed malignant and 
benign population (n=6) 
Not suitable intervention (n=6) 
Not suitable outcomes (n=5) 
Outdated intervention/co-interventions (n=5) 
Conference abstracts/posters (n=4) 
Reviews (n=3) 
Retracted (n=2) 
Patients < 16 years (n=1) 
Article not retrievable (n=1) 
Second publication of same study (n=1) 




Studies included in 
qualitative synthesis  
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Table 2. Summary of risk of bias of observational studies 
Author  
year 
Type of bias  
Selection bias and 
confounding 


























Authors did not 
describe dose 
given 
No comment Unknown whether 
all patients died, 




that some patients 
are still alive 
 






indication for PN in 
one-third of the 
population  
Dose administered 
and composition of 
PN not described 
Large range of 
performance 



























































a et al. 
2006 
No comment Dose administered 
and administration 



























N, sex, age, cancer diagnosis, tumour 
stage, anti-neoplastic treatment, PS, NS, 
inclusion and exclusion criteria 
PN indication 
Medical related, 
Food/nutrition related  
PN intervention  
Composition of PN solution, administration, rate, 
dose planned, dose administered and duration of 
PN  
Randomized controlled trials 






N=47 (22 PN vs. 25 control) 
Sex: Female (n=7 vs. 10), male (n=15 vs. 
15) 
Age, mean (range): 67.4 (41.5-81.6) vs. 
65.9 (43.3-88.2) 
Cancer diagnosis: GI cancer 
Tumour stage: locally advanced or 
metastatic 
Anti-neoplastic treatment: CT (n=20 vs. 
n=23) 
PS: KPS 0 (n=1 vs. 5), 1 (n=12 vs. 13), 2 
(n=9 vs. 7) 
NS: WL < 5% (n=1 vs. 7), 5-10% (n=6 vs. 
4), > 10% (n=15 vs. 14). Sarcopenia 
assessed by BIA (n=2 vs. 1), sarcopenia 
assessed by handgrip strength (n=9 vs. 
9). NRS2002: score ≥2 (all patients) 
Inclusion criteria: Incurable GI cancer, 
age > 18, PS 0-2, NRS2002 >2 
Exclusion criteria: functional or actual 
short bowel syndrome 
Medical related: to 
prevent and treat 
functional decline 
accompanying cachexia 
in patients at nutritional 
risk (≥ 2 by NRS2002) 
 
Food/nutrition intake: 
> 75% of energy 
requirement (n=20 vs. 
23), > 75% of protein 
requirement (n=10 vs. 
12) 
PN arm: supplemental PN + nutritional 
counselling 
Composition: 3-chamber bag (Olimel N9E., 
Baxter); 56.9 g protein, 1070 kcal and 40 g fat/L 
Administration: tunnelled CVC (n=15), 
transthoracic venous port (n=3), PICC line (n=3)  
Rate: NR 
Dose planned: supplemental PN to reach 30 
kcal/kg/d and 1.5 g protein/kg/d 
Dose given: typically 25-35% of daily nutritional 
requirement 
Duration: 24 weeks 
 
Control arm: 
Dietetic counselling to ensure intake >75% of 
nutritional requirement (advice to address eating 
difficulties and stimulate intake, supplemental 
ONS when protein and calorie intake was unmet 
by food; EN offered if nutrient intake was below 
75% of nutritional needs) 
 
Oh et al. 
(2014) 
 
N=31 (15 PN vs. 16 control) 
Sex: Female (n=6 vs. 6), male (n=10 vs. 
9) 
Age, mean (SD): 60.4±12.6 vs. 59.1 ±9.6  
Medical related: 
Feeding via enteral 
route not possible 
 
PN arm: 
Composition: any type of marketed amino acid 




















Hepatobiliary/pancreas (n=8 vs. 2), colon 
(n=3 vs. 4), stomach (n=0 vs. 4), breast 
(n=2 vs. 1), neuroendocrine (n=0 vs. 2), 
lung (n=0 vs. 1), prostate (n=0 vs. 1), 
melanoma (n=1 vs. 0), salivary gland 
(n=0 vs. 1), leukaemia (n=1 vs. 0) 
Tumour stage: advanced terminal 
cancer, no further plans of active 
treatment  
Anti-neoplastic treatment: None 
PS: ECOG 3 (n=11 vs. 6), ECOG 4 (n=5 
vs. 9)  
NS: BMI < 18.5 (n=4 vs. 1)  
Inclusion criteria: advanced cancer with 
no further plans for anti-neoplastic 
treatment, inability to feed via an enteral 
route, age > 19, life expectancy ≤ 12 
weeks, PS 3-4, presence venous access, 
admission to hospital for a minimum of 1 
day 
Exclusion criteria: cardiac or renal 
disease that restricted administration of 
fluid, electrolyte imbalance, poorly 
controlled diabetes, indication of 
unsuitability 
Food/nutrition related: 
no feeding per os 
Administration: NR 
Rate: NR 
Dose planned, mean (SD): 1286.6 kcal/d (108.3) 
and 59.6 g protein/d 
Dose given, average: 1286 kcal/day  
Duration: until death or withdrawal of consent, 
not further specified 
 
Control arm: 
Intravenous fluid therapy with a maximum of 30 
mL/kg/d (fluid consisted of saline, half saline or 
dextrose water). Maximum calories administered 
limited to under 20 kcal/kg/d (physician decision) 
Dose, mean: 374.7±71.7 kcal/d 









Sex: female (n=54), male (n= 57)  
Age, median (range): 62 (32-79) 
Cancer diagnosis: stomach (n=38), 
colorectal (n=21), pancreas/biliary (n=20), 
oesophagus (n=10), lung (n=10), ovary 




short bowel syndrome 
(high output ileostomy/ 
fistula) (n=14), EN not 
Composition: all-in-one bag 
Administration route: NR 
Rate: 10-14 hours overnight 
Dose planned: 20-25 kcal/kg/d (bedridden), 25-
30 kcal/kg/d (outpatients) + 1.0-1.5 g amino 
acids/kg/d 












Tumour stage: stage III (n=25), stage IV 
(n=86) 
Anti-neoplastic treatment: CT (n=61), 
RT (n=2), CRT (n=9) 
PS: KPS, median (range): 70 (60-80) 
NS: PG-SGA B (n=41) or PG-SGA C 
(n=70); WL, median (range): 11.7% (0-
38.3%); BMI, median (range): 20.7 (13.5-
29.5) 
Inclusion criteria: adult cancer patients 
candidates for PN according to ESPEN 
guidelines, proven and prolonged failure 
to meet nutrition  requirements by 
oral/enteral route with impending risk of 
death due to malnutrition, life expectancy 
> 2 months, KPS > 50, control of pain, 
absence of severe organ dysfunction, 
presence of environmental conditions 
compatible with PN 
Exclusion criteria: Not specified 





(oral intake (kcal/d), 
median (range): 500 
(200-1300) 
Duration, median (range): 137 days (21-576)  
 







Sex: not reported 
Age, mean (SD): 60 (4.3) 
Cancer diagnosis: gastrointestinal 
(n=38), gynaecological (n=10), other 
(n=37, urinary, unknown and pelvic) 
Tumour stage: NR, stated as advanced 
cancer 
Anti-neoplastic treatment: CT (n=26) 
PS: ECOG, mean (SD): 1.5 (0.5) 
NS: BMI, mean (SD): 21.6 (4.3); 
malnourished (assessed by MUST) 
(n=43)  
Medical related: 





Composition: glucose 3-6 g/kg/d, amino acids 
1.0 g/kg/d, lipids < 1 g/kg/d, EAA 7-10 g/d + 
vitamins/trace elements added if needed 
Administration: Peripherally CVC  
Rate: Intermittent infusion, primarily at night-time 
Dose planned: 20-35 kcal/kg/d 
Dose given: NR 
Duration, mean (SD): 54.13 days (114.99) (GI), 
60.7 days (44.49) (gynaecological), 34.29 days 












Inclusion criteria: advanced cancer and 
intestinal occlusion with peritoneal 
carcinomatosis, considered candidates 
for active chemotherapy 
Exclusion criteria: patients not 













Sex: female (n=190), male (n=224) 
Age, median (range): 62 (16-90) 
Cancer diagnosis: head & neck (n=50), 
stomach (n=92), small bowel-biliary 
(n=10), colorectal (n=84), ovary (n=51), 
pancreas (n=46), other (n=81) 
Tumour stage: metastatic (n=276), vital 
organ metastasis (n=170), locoregional 
disease (n=105) 
Anti-neoplastic treatment: None 
PS: KPS, median (range): 60 (20-100)  
NS: WL (habitual weight), median 
(range): 24% (-8 to -56); WL (previous 6 
months), median (range): 16% (-44 to -
50); BMI, median (range): 19.5 (12.8-
30.0) 
Inclusion criteria: adults with no/negible 
oral/enteral nutrition, incurable 
malignancy without major organ failure or 
major involvement of a vital organ or 
severe metabolic derangement 
Exclusion criteria: patients with ascites 
or pleural effusion, uncontrolled 
symptoms, receiving PN in the 
Medical related: 
SBO/sub-obstruction 







Rate: daily infusion 
Dose planned: at least 25 kcal/kg/d and 1 g 
amino acid/kg/d 
Dose given: NR 
Duration: until death (n=273); 
Premature PN discontinuation, median (range): 2 












perspective to become candidates for 
future oncologic treatment 







Sex: female (n=31), male (n=21) 
Age, mean (SD): 53.2 (9.4) 
Cancer diagnosis: pancreas (n=14), 
colorectal (n=11), ovarian (n=6), appendix 
(n=5), stomach (n=4), other cancers 
(n=12) 
Tumour stage: stage IV, with multiple 
organ involvement 
Anti-neoplastic treatment: all patients 
received either CT, RT or hormonal 
therapy 
PS: KPS, mean (SD): 60.1 (10.8) 
NS: PG-SGA B (n=19), PG-SGA C 
(n=33); WL previous 6 months, mean 
(SD): 16.9% (9.3)  
Inclusion criteria: cancer, expected 
survival > 90 days, no PN prior to hospital 
admission, no associated liver or kidney 
problems, cancer cachexia with tumor 
burden involving multiple organs and 
compromised GI function 
Exclusion criteria: patients who did not 





Poor oral intake, PN 
only nutritional option 
Composition: Total Nutrient Admixture solution 
(lipids < 30E%), amino acids and dextrose) + 
Multivitamin Infusion-13 & Multitrace 5.  
Administration: NR 
Rate: daily cycled infusion 
Dose planned: 25-30 kcal/kg (BMI <30), 22-25 
kcal/kg of ideal body weight (BMI≥30). Protein 1.5 
to 2.5 g/kg depending on BMI.  
Dose given, mean (SD): 1468 kcal/d (328), 81.1 
g protein/d (16.4) 
(PN less than 3 months) vs. 1273 kcal/d (238), 
70.0 g protein/d (14.6) (PN more than 3 months) 
Duration, mean (range): 3.4 months (0.4-11.7) 





Sex: female (n= 14), male (n=18) 




Composition: Amino acids 1.2-1.5 g/kg, lipids at 
least 35 E%, additional vitamins or electrolyte if 















Cancer diagnosis: inoperable pancreatic 
cancer 
Tumour stage: IV 
Anti-neoplastic treatment: Not reported 
PS: NR 
NS: > 5% WL previous 4 weeks OR BMI 
< 19 
Inclusion criteria: ambulant patients with 
stage IV pancreatic cancer, weight loss > 
5 % in four weeks or BMI < 19 in spite of 
enteral and drug support 
Exclusion criteria: not specified 
and loss of appetite 
(most of the patients) 
Food/nutrition related: 
WL > 5% in previous 
four weeks or BMI <19 
(despite caloric 
supplement 200-400 ml, 
1.5 kcal/ml combined 
drug support) 
Rate: overnight infusion to reach targeted calorie 
intake in 5 of 7 days 
Dose planned: 25 kcal/kg/d in 5 of 7 days: amino 
acids 1.2-1.5 g/kg, lipids at least 35 E%, 
additional vitamin or electrolyte if indicated. (given 
dose not reported) 
Dose given: NR 
Duration, median (range): 18 weeks (8-35) 








Sex: female (n= 107), male (n=45) 
Age: median (range): 59.5 (22-88) 
Cancer diagnosis: stomach (n=48), 
ovaries (n=42), colorectal (n=30), 
endometrium (n=7), breast (n=6), ileum 
(n=5), gallbladder (n=4), pancreas (n=3), 
kidney (n=2), skin (n=1), prostate (n=1), 
abdominal sarcoma (n=1), unknown (n=2) 
Tumour stage: Considered terminal 
(unresponsive to oncologic treatment) 
Anti-neoplastic treatment: None 
PS: 90 patients had KPS ≤40, 40 had 
KPS ≥ 50, 18 had a KPS= 60 and 4 had a 
KPS = 70 
NS: Mean (SD) WL (kg) previous 6 
months: 9.5 (4.7), range WL: 2-26 kg. 
BMI, mean (SD): 20.1 (3.6) 
Inclusion/exclusion criteria: not 
specified 
Medical related: 




Food/nutrition related:  
Food intake not possible 
 
Composition: All-in-one bags containing amino 




Dose: 20- 30 kcal/kg/d, 3-4 gram/kg body weight 
of carbohydrates, 1-1.5 gram/kg body weight 
protein and 1 gram/kg body weight of lipids 












BIA: Bioimpedance; BMI: body mass index; CRT: concurrent chemo-radiation; CT: chemotherapy; CVC: central venous catheter; E%: 
energy percent; ECOG: Eastern Cooperative Oncology Group; EN; enteral nutrition; kcal: kilocalories; KPS: Karnofsky Performance 
Status; NR: not reported; NRS2002: Nutritional Risk Screening 2002; NS: nutritional status; ONS: oral nutritional support; PG-SGA: 
Patient-Generated Subjective Global Assessment; PN: parenteral nutrition; PS: performance status; QoL: quality of life, RT: radiotherapy; 

























Obling et al. 2017 Good 91 % Good 
Oh et al. 2014 Dysfunctional 0 % Poor  
Cotogni et al. 2017 Dysfunctional 65 % Good   
Guerra et al. 2015 Dysfunctional 47 % Good   
Bozzetti et al. 2014 Dysfunctional 0 % Any  
Vashi et al. 2014 Dysfunctional 100 % Any  
Pelzer et al. 2010 Dysfunctional  Unknown Unknown 
Santarpia et al. 2006 Dysfunctional 0 % Any 





















HRQoL and physical function Nutritional status Survival Adverse 
events 




HRQoL (EORTC QLQ-C15 
PAL): Mean ∆ +16.0 score in 
favour of PN at week 12 




reported physical function 
(EORTC QLQ-C15): NS at any 
time point 
 
Performance testing: HGS and 
6MWT NS at any time point 
 
Fat free mass (BIA): Mean ∆ fat 
free mass 6.44 kg (SD 2.9-10.0), 
p<0.05 at week 12, in favour of PN 
arm. NS difference at week 6, 18 
or 24.  
 
BMI: mean ∆ 1.65 kg/m2 (SD 0.4-
2.9), p<0.05 at week 12, in favour 
of PN arm. NS at week 6, 18 or 24  
 
 
mOS NS different between 
groups (mOS 168 days (95% CI 
80-268) PN vs. 169 days (88-
295) in control group)  
n=11 in PN arm vs. n=11 in 
control arm still alive at week 24, 
n=3 in PN arm vs. n=5 in control 









Oh et al. 
(2014) 
 
NA NA mOS in the PN group 13 (95% CI 
3.1-22.9) days vs. 8 (95% CI 5.7-
10.3) days in the control group. 
NS difference between groups. 
NA 





HRQoL (EORTC QLQ C-30): 
improvement over time in 
global HRQoL, mean (SD) 52 
(17) at baseline, 58 (17) at 1 
month, 66 (17) at 2 months, 71 
(14) at 3 months and 66 (16) at 
4 months (p<0.001).  
 
NA mOS (range): 4.7 months(1-42) 
(n=47).  
n=74 alive at 3 months 
n=38 alive at 6 months 
 
24 of 72 patients on concurrent 
oncologic treatment died vs. 23 of 






















reported physical function 
(EORTC QLQ C-30) improved 
at all time points, mean (SD) 38 
(22) at baseline, 42 (22) at 1 
month, 46 (21) at 2 months, 55 






NA NA mOS (range): 40 days (2-702).  
Outpatients survived longer than 
inpatients (log rank: 7.090, p= 
0.008). Patients who started 
concurrent oncologic treatment 
during or after PN (n=28) lived 
longer than those who did not 
(log rank: 17.316, p<0.001). 
Patients who started 
chemotherapy during or after 
start of PN survived longer than 
those who did not (log rank: 
17.316, p<0.001). Twenty-eight 
could receive chemotherapy after 













NA NA mOS (95% CI): 3.0 months (2.7-
3.3).  
In cachectic patients (n=143): 3- 






























HRQoL (EORTC QLQ-C30): 
Unchanged at 1 month, 
improved score at 2 months 
(mean ∆ +12, p<0.02) and at 3 
months (mean ∆ +16, p<0.02).  
Every month on PN associated 
with improved global HRQoL 
by 6.3 points (p<0.001). 
 
Physical function: Self-
reported physical function 
(EORTC QLQ-C30) improved 
at 2 months (mean ∆ score 
+14, p<0.02) and at 3 months 
(mean ∆ +24, p<0.02). Every 
month on PN associated with 
improved physical HRQoL 
domain by 6 points (p<0.005). 
 
SGA global rating: Improved at 
all time points (p<0.05).  
At baseline: A (n=0), B (19), C 
(33). At 1 month on PN: A (n=2), B 
(n=20), C (n=17); at 2 months on 
PN: A (n=3), B (n=13), C (n= 6); at 
3 months on PN: A (n=2), B 
(n=12), C (n=1). 
 
Body weight: Improved at 1 
month: mean ∆ 1.6, p<0.03, at 2 
months: mean ∆ 2.4, p<0.04, at 3 
months: mean ∆ 4.8, p< 0.04. 
Every month on PN associated 
with improved weight by 1.3 kg 
(p=0.009).  
mOS: 5.1 months (95% CI: 2.8-
7.3)  
mOS: 6.4 months (KPS ≤ 50) vs. 
4.6 months (KPS > 50) 
mOS: 3.2 months (SGA-B) vs. 
6.5 months (SGA-C)  
n=25 survived < 6 months, n=27 
survived > 6 months, n=12 
survived > 1 year (of those 5 
patients survived > 2 years)  
1 of 9 patients 














NA BMI, median (range): increased 
from 19.7 (14.4-25.9) to 20.5 
(15.4-25.0) during treatment (no p 
value or effect per time given) 
NA No severe side 
effects observed 








Physical function: Subgroup 
analysis in patients alive at >60 
and >90 days: NS change in 
KPS from baseline to 1 month 
Body weight and BMI: Subgroup 
analysis in survivors >60 days 
(n=64) and >90 days (n=39): 
Increased from 51.7 kg ±10.3 
(baseline) to 53.2 kg ±10.3 (1 
month) (p<0.0001) and 50.5 kg 
mOS (range): 45 days (6-1269)  
 
n=56 survived > 30 days, n=34 
survived 31-60 days, n=25 
survived 61-90 days, n=37 












±10.2 (baseline) to 52.0 kg ±10.1 
(1 month) (p<0.0001). Mean BMI 
increased from 19.6 kg/m2 ±3.1 
(baseline) to 20.1 kg/m2 ±03.1 (1 
month) (p<0.0001) and 19.2 kg/m2 
±3.2 (baseline) to 20.0 kg/m2 ±3.2 
(1 month) (p<0.0001). No results 
presented in survivors < 60 days. 
 
∆: difference; 6MWD: six-minute walk distance; BIA: Bioimpedance; BMI: body mass index; CI: confidence interval; HGS: hand grip 
strength; HRQoL: health-related quality of life; KPS: Karnofsky Performance Status; m: metre; mOS: median overall survival; NA: not 
applicable; NS: not significant; SGA: Subjective Global Assessment; SGA-A: well nourished; SGA-B: moderately malnourished; SGA-C: 
severely malnourished; PN: parenteral nutrition; SD: standard deviation; vs: versus 
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